June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Noninvasive Dexamethasone Sodium Phosphate Ocular Drug Delivery System for the Treatment of Intermediate and Posterior Uveitis
Author Affiliations & Notes
  • Kongnara Papangkorn
    Aciont Inc, Salt Lake City, UT
    University of Utah, Salt Lake City, UT
  • Donald Mix
    Aciont Inc, Salt Lake City, UT
  • Charlotte Butler
    Aciont Inc, Salt Lake City, UT
  • John Higuchi
    Aciont Inc, Salt Lake City, UT
  • Balbir Brar
    Aciont Inc, Salt Lake City, UT
  • William Higuchi
    Aciont Inc, Salt Lake City, UT
    University of Utah, Salt Lake City, UT
  • Footnotes
    Commercial Relationships Kongnara Papangkorn, Aciont Inc (E); Donald Mix, Aciont, Inc (E); Charlotte Butler, Aciont Inc (E); John Higuchi, Aciont Inc. (E); Balbir Brar, Aciont Inc (C), Atheronova Inc (C), Imprimis Pharma (C); William Higuchi, Aciont Inc. (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3206. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kongnara Papangkorn, Donald Mix, Charlotte Butler, John Higuchi, Balbir Brar, William Higuchi; Noninvasive Dexamethasone Sodium Phosphate Ocular Drug Delivery System for the Treatment of Intermediate and Posterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3206.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To assess the efficacy and safety of dexamethasone sodium phosphate Visulex system (DSP-V) with various dosing regimens in treating intermediate and posterior uveitis in New Zealand white (NZW) rabbit.

 
Methods
 

Fifteen NZW rabbits were assigned to 5 groups according to DSP concentration, dosing, and Visulex application time (see table). Uveitis was induced in NZW rabbits by subcutaneous injections of complete Freund’s adjuvant and an IVT injection of H37 RA antigen as described by Cheng, et. al. After induction, DSP treatment was given to the right eye of each rabbit by DSP-V except the control group. Efficacy and safety of DSP-V were evaluated daily by indirect ophthalmoscopy (IO) and at the end of the study by histopathological examinations (HE) to evaluate the pathology and inflammatory cell infiltration (ICI) into the eye tissues including both anterior (conjunctiva, cornea, anterior chamber) and posterior sections (vitreous, choroid, retina).

 
Results
 

The control group exhibited significant inflammation in the vitreous, choroid, and retina; and slight or no inflammation in the conjunctiva, cornea, anterior chamber, and iris. All treatments with DSP-V showed effectiveness in the reduction of vitreous opacity (VO) and ICI of the vitreous, choroid, and retina. The VO of the control group indicate that uveitis occurred within 24 h after induction and remained throughout the 29 day study. After Day 3, there was a clear differentiation between the control and the 10 and 15 min treatment groups. By Day 10, the highest dosing regimen (Group 2) showed complete resolution of the vitreal inflammation and by Day 21, the lowest dosing regimen (Group 5) was also completely clear. With the exception of the 8% single dose treatment, there appears to be a DSP dose-efficacy relationship. As for the safety of DSP-V, the differences in inflammation scores between the treatment and control groups would imply DSP-V is a safe modality for uveitis treatment. The HE also supports the safety aspect of DSP-V treatment.

 
Conclusions
 

DSP-V containing 8% to 15% DSP administered for 5 to 15 min is well tolerated and highly efficacious in this chronic intermediate and posterior uveitis model. Even a single dose of 8% DSP can suppress intermediate and posterior uveitis for 29 days.

     
Keywords: 746 uveitis-clinical/animal model • 557 inflammation • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×